{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:46:46Z","timestamp":1792039606870,"version":"4.4.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lungcan.2026.109602","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:12:18Z","timestamp":1788221538000},"page":"109602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion"],"prefix":"10.1016","volume":"221","author":[{"given":"Christoper","family":"Hooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Bowen","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Faivre-Finn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rulach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Walls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.lungcan.2026.109602_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0010","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12890-025-03715-9","article-title":"Real-world treatment patterns and outcomes for patients with non-metastatic non-small cell lung cancer: retrospective analyses in Canada, England, and Germany","volume":"25","author":"Greystoke","year":"2025","journal-title":"BMC Pulm Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11912-023-01477-3","article-title":"Resectability versus operability in early-stage non-small cell lung cancer","volume":"26","author":"Streit","year":"2024","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.lungcan.2026.109602_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.108061","article-title":"An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer","volume":"199","author":"Houda","year":"2025","journal-title":"Lung Cancer."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109602_b0025","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.3747\/co.27.6047","article-title":"Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada","volume":"27","author":"Seung","year":"2020","journal-title":"Curr Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109602_b0030","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/annonc\/mdv187","article-title":"2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer","volume":"26","author":"Eberhardt","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109602_b0035","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0040","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.resinv.2019.03.011","article-title":"Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria","volume":"57","author":"Sakaguchi","year":"2019","journal-title":"Respir Investig."},{"key":"10.1016\/j.lungcan.2026.109602_b0045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.radonc.2019.11.015","article-title":"Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer","volume":"144","author":"Shaverdian","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.586449","article-title":"Consolidation immunotherapy after platinum-based chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer-cross-sectional study of eligibility and administration rates","volume":"10","author":"Eichkorn","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0055","doi-asserted-by":"crossref","unstructured":"Curran WJ, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011 Oct 5;103(19):1452\u201360. doi:10.1093\/jnci\/djr325 PubMed PMID: 21903745; PubMed Central PMCID: PMC3186782.","DOI":"10.1093\/jnci\/djr325"},{"issue":"13","key":"10.1016\/j.lungcan.2026.109602_b0060","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109602_b0065","doi-asserted-by":"crossref","first-page":"423","DOI":"10.21037\/jtd-22-925","article-title":"Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer","volume":"15","author":"Gouran-Savadkoohi","year":"2023","journal-title":"J Thorac Dis."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103464","article-title":"Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R","volume":"9","author":"Filippi","year":"2024","journal-title":"ESMO Open."},{"issue":"216","key":"10.1016\/j.lungcan.2026.109602_b0075","article-title":"Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving treatment paradigms","volume":"15","author":"Horne","year":"2026","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109602_b0080","doi-asserted-by":"crossref","unstructured":"Zer A, Ahn MJ, Barlesi F, Bubendorf L, Ruysscher DD, Garrido P, et al. Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2025 Aug 28;0(0). doi:10.1016\/j.annonc.2025.08.003 PubMed PMID: 40885528.","DOI":"10.1016\/j.annonc.2025.08.003"},{"key":"10.1016\/j.lungcan.2026.109602_b0085","doi-asserted-by":"crossref","unstructured":"Detterbeck FC, Woodard GA, Bader AS, Dacic S, Grant MJ, Park HS, et al. The Proposed Ninth Edition TNM Classification of Lung Cancer. CHEST. 2024 Oct;166(4):882\u201395. doi:10.1016\/j.chest.2024.05.026.","DOI":"10.1016\/j.chest.2024.05.026"},{"key":"10.1016\/j.lungcan.2026.109602_b0090","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute.; 2025."},{"issue":"10","key":"10.1016\/j.lungcan.2026.109602_b0095","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109602_b0100","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/ijms20030593","article-title":"Idiopathic pulmonary fibrosis and lung cancer: mechanisms and molecular targets","volume":"20","author":"Ballester","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"12","key":"10.1016\/j.lungcan.2026.109602_b0105","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.rmed.2007.07.012","article-title":"The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK","volume":"101","author":"Le Jeune","year":"2007","journal-title":"Respir Med."},{"key":"10.1016\/j.lungcan.2026.109602_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108873","article-title":"Radiotherapy outcomes in patients with interstitial lung disease and interstitial lung abnormalities: adverse events and survival from a UK tertiary centre","volume":"211","author":"Bowen Jones","year":"2026","journal-title":"Lung Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oncolo\/oyac226","article-title":"Management of lung cancer in the patient with interstitial lung disease","volume":"28","author":"Frank","year":"2023","journal-title":"The Oncologist."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109602_b0120","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/life14111506","article-title":"Perioperative anti-fibrotic treatment prevents acute exacerbation of idiopathic pulmonary fibrosis after lung cancer surgery","volume":"14","author":"Bongiolatti","year":"2024","journal-title":"Life."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0125","article-title":"Lung cancer resection in patients with underlying usual interstitial pneumonia: a meta-analysis","volume":"10","author":"Patel","year":"2023","journal-title":"BMJ Open Respir Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1053\/j.semtcvs.2024.11.003","article-title":"Systematic review of the comparative studies of image-guided thermal ablation, stereotactic radiosurgery, and sublobar resection for treatment of high-risk patients with stage I non-small cell lung cancer","volume":"37","author":"Pennathur","year":"2025","journal-title":"Semin Thorac Cardiovasc Surg."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109602_b0135","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.ijrobp.2017.03.010","article-title":"Treatment-related toxicity in patients with early-stage non-small cell lung cancer and coexisting interstitial lung disease: a systematic review","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0140","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaoncol.2023.7269","article-title":"Stereotactic radiation therapy in early non-small cell lung cancer and interstitial lung disease: a nonrandomized clinical trial","volume":"10","author":"Palma","year":"2024","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0145","first-page":"902","article-title":"A primer on interstitial lung disease and thoracic radiation","volume":"15","author":"Goodman","year":"2020","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109602_b0150","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.7150\/jca.24936","article-title":"Impact of interstitial lung disease classification on the development of acute exacerbation of interstitial lung disease and prognosis in patients with stage iii non-small-cell lung cancer and interstitial lung disease treated with chemoradiotherapy","volume":"9","author":"Kobayashi","year":"2018","journal-title":"J Cancer."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0155","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-015-2775-y","article-title":"Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia","volume":"76","author":"Watanabe","year":"2015","journal-title":"Cancer Chemother Pharmacol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109602_b0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ijrobp.2014.02.011","article-title":"Pulmonary artery invasion, high-dose radiation, and overall survival in patients with non-small cell lung cancer","volume":"89","author":"Han","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0165","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13014-017-0772-5","article-title":"Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy?","volume":"12","author":"Ma","year":"2017","journal-title":"Radiat Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0170","first-page":"61","article-title":"CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer","volume":"25","author":"Walls","year":"2020","journal-title":"Clin Transl Radiat Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0175","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.prro.2023.04.004","article-title":"Treatment of oligometastatic non-small cell lung cancer: an ASTRO\/ESTRO clinical practice guideline","volume":"13","author":"Iyengar","year":"2023","journal-title":"Pract Radiat Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.lungcan.2022.07.016","article-title":"Vascular invasion identifies the most aggressive histologic subset of stage I lung adenocarcinoma: Implications for adjuvant therapy","volume":"171","author":"Yambayev","year":"2022","journal-title":"Lung Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0185","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0190","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1503\/cmaj.050051","article-title":"A global clinical measure of fitness and frailty in elderly people","volume":"173","author":"Rockwood","year":"2005","journal-title":"CMAJ Can Med Assoc J J Assoc Medicale Can."},{"key":"10.1016\/j.lungcan.2026.109602_b0195","unstructured":"Lung cancer statistics | Cancer Research UK [Internet]. [cited 2026 Apr 22]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/lung-cancer."},{"issue":"9","key":"10.1016\/j.lungcan.2026.109602_b0200","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.21037\/tlcr-24-241","article-title":"Incidence, prevalence, and survival of lung cancer in the United Kingdom from 2000\u20132021: a population-based cohort study","volume":"13","author":"Corby","year":"2024","journal-title":"Transl Lung Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2010.08.009","article-title":"The Frailty Syndrome: Definition and Natural History","volume":"27","author":"Xue","year":"2011","journal-title":"Clin Geriatr Med."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0210","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/gerona\/glp012","article-title":"Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries","volume":"64","author":"Santos-Eggimann","year":"2009","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109602_b0215","article-title":"Impacts of frailty on prognosis in lung cancer patients: a systematic review and meta-analysis","volume":"22","author":"Dai","year":"2021","journal-title":"Front Med."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109602_b0220","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/1055-9965.EPI-25-1099","article-title":"Burden and impact of frailty and comorbidity in individuals screened for lung cancer","volume":"35","author":"Henderson","year":"2026","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109602_b0225","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ijrobp.2017.03.011","article-title":"Plasma levels of IL-8 and TGF-\u03b21 predict radiation induced lung toxicity in non-small cell lung cancer patients: a validation study","volume":"98","author":"Wang","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.lungcan.2026.109602_b0230","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.radonc.2020.10.040","article-title":"Radiomics analysis of 3D dose distributions to predict toxicity of radiotherapy for lung cancer","volume":"155","author":"Bourbonne","year":"2021","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0235","doi-asserted-by":"crossref","unstructured":"Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic Evaluation of the Patient With Lung Cancer Being Considered for Resectional Surgery: Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2013 May 1;143(5, Supplement):e166S-e190S. doi:10.1378\/chest.12-2395.","DOI":"10.1378\/chest.12-2395"},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0240","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-047376","article-title":"Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study","volume":"11","author":"Ostwal","year":"2021","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0245","article-title":"UK national observational cohort study investigating tolerance of anti-cancer systemic therapy in the elderly: the TOASTIE study","volume":"3","author":"Baxter","year":"2024","journal-title":"BMJ Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0250","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1183\/09031936.00184308","article-title":"ERS\/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy)","volume":"34","author":"Brunelli","year":"2009","journal-title":"Eur Respir J."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109602_b0255","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.clon.2022.08.028","article-title":"Prehabilitation and rehabilitation for patients with lung cancer: a review of where we are today","volume":"34","author":"Burnett","year":"2022","journal-title":"Clin Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2026.109602_b0260","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.clon.2024.02.002","article-title":"Prehabilitation for patients with cancer undergoing radiation therapy: a scoping review","volume":"36","author":"Harris","year":"2024","journal-title":"Clin Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108572","article-title":"Feasibility, acceptability and clinical outcomes of a real-world, regional lung cancer prehabilitation programme for patients undergoing curative intent radiotherapy","volume":"204","author":"Gourlay","year":"2025","journal-title":"Lung Cancer."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109602_b0270","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1017\/S146039692100008X","article-title":"Is IMRT or VMAT superior or inferior to 3D conformal therapy in the treatment of lung cancer? A brief literature review","volume":"21","author":"Afrin","year":"2022","journal-title":"J Radiother Pract."},{"issue":"8","key":"10.1016\/j.lungcan.2026.109602_b0275","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.jtho.2022.05.003","article-title":"Avoiding toxicity with lung radiation therapy: an IASLC perspective","volume":"17","author":"Bucknell","year":"2022","journal-title":"J Thorac Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0360-3016(91)90168-4","article-title":"Dose-volume histograms","volume":"21","author":"Drzymala","year":"1991","journal-title":"Int J Radiat Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0285","doi-asserted-by":"crossref","first-page":"933","DOI":"10.5603\/RPOR.a2022.0110","article-title":"Contralateral esophageal sparing technique in definitive radiotherapy for non-small cell lung cancer: dosimetric parameters and normal tissue complication probability modeling","volume":"27","author":"\u0141azar-Poniatowska","year":"2022","journal-title":"Rep Pract Oncol Radiother."},{"issue":"6","key":"10.1016\/j.lungcan.2026.109602_b0290","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamaoncol.2021.0281","article-title":"Assessment of a contralateral esophagus\u2013sparing technique in locally advanced lung cancer treated with high-dose chemoradiation: a phase 1 nonrandomized clinical trial","volume":"7","author":"Kamran","year":"2021","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109602_b0295","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother Oncol."},{"key":"10.1016\/j.lungcan.2026.109602_b0300","doi-asserted-by":"crossref","unstructured":"Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. With particular reference to bronchogenic carcinoma. Cancer. 1948;1(4):634\u201356. doi:10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L.","DOI":"10.1002\/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L"},{"key":"10.1016\/j.lungcan.2026.109602_b0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108276","article-title":"167 CONCORDE: a multicentre phase Ib Trial of DNA damage response inhibitors and durvalumab consolidation in patients with unresectable stage IIB\/III NSCLC undergoing radiotherapy: the newcastle experience","volume":"200","author":"Greystoke","year":"2025","journal-title":"Lung Cancer."},{"key":"10.1016\/j.lungcan.2026.109602_b0310","doi-asserted-by":"crossref","unstructured":"Horne A, Payne A, Crawford H, Dempsey C, Mistry H, Price G, et al. The VIGILANCE Study Protocol: An Innovative Study to Identify Prognostic and Response Biomarkers in Patients with Stage III Non-Small-Cell Lung Cancer Treated with Curative-Intent Radiotherapy. BioMed. 2025 Nov 12;5(4). doi:10.3390\/biomed5040027.","DOI":"10.3390\/biomed5040027"},{"key":"10.1016\/j.lungcan.2026.109602_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108663","article-title":"An introduction to pragmatic trials in lung cancer research: a multi-faceted approach","volume":"206","author":"Bowen Jones","year":"2025","journal-title":"Lung Cancer."},{"issue":"11","key":"10.1016\/j.lungcan.2026.109602_b0320","first-page":"1598","article-title":"IASLC Advanced Radiation Technology Committee. Intensity-modulated radiotherapy for lung cancer: current status and future developments","volume":"9","author":"Chan","year":"2014","journal-title":"J Thorac Oncol Off Publ Int Assoc Study Lung Cancer."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109602_b0325","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.ijrobp.2013.05.003","article-title":"Effect of normal lung definition on lung dosimetry and lung toxicity prediction in radiation therapy treatment planning","volume":"86","author":"Wang","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600663X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022600663X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:09:56Z","timestamp":1792037396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022600663X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":65,"alternative-id":["S016950022600663X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109602","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109602"}}